Second, OCD symptoms are bi-directionally regulated during treatment of opioid use disorder: initially, a reduction in symptoms is observed during induction into treatment when patients receive higher doses of MOR agonists, whereas an exacerbation is observed upon agonist titration (60–64). The gene discussed is OPRM1; the disease is opioid use disorder.